Clinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
NCT02730312 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
- Lead sponsor
- Xencor, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2016
- Completion date
- September 30, 2021
- Enrollment
- 120 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
acute myelogenous leukemia, b-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, chronic myeloid leukemia, blast crisis